Topic: infectious respiratory diseases
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
Four years ago, J&J splashed out $1.75 billion to take control of antiviral firm Alios, but the lead drug from that deal now seems to be in trouble.
Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.
Armed with positive phase 2b data, resTORbio is planning pivotal trials next year for a drug to prevent respiratory tract infections in the elderly.
Qiagen will gain control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.
Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.